Light Chain Bioscience Chooses Genedata to Digitalize Cell Line & Bioprocess Development

Off-the-shelf workflow platform accelerates development of manufacturing processes for innovative biotherapeutics

June 26, 2023
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Light Chain Bioscience, a brand of Novimmune, has chosen the Genedata Bioprocess^® enterprise platform to streamline and automate cell line and early bioprocess development of their lead candidates.

“With our pipeline of bispecific and multi-specific drug candidates rapidly growing, we needed a workflow management system that also captures all the data generated by our CDMOs and integrates them with our in-house experimental results. Genedata Bioprocess allows us to keep track of our process development workflows and increases throughput to ensure that we develop efficient and scalable manufacturing processes for our proprietary drugs,” said Walter Ferlin, Ph.D., CSO. “Being able to integrate the system with Genedata Biologics^®, our existing biologics discovery workflow platform, also gives us company-wide access to both research and development data in one shared platform, which is so valuable because we can trace everything — all the way back from manufacturing through development to initial candidate selection,” said Nicolas Fischer, Ph.D., CEO at Light Chain Bioscience.

Light Chain Bioscience focuses on the development of innovative therapies using their proprietary technologies to discover and develop bispecific and multi-specific therapeutic antibodies that fully retain the native sequence and structure of human antibodies. Genedata Bioprocess is fully integrated with Genedata Biologics and supports the entire end-to-end development process at Light Chain Bioscience across CLD, USP, DSP, and analytics operations.

Co-developed over the last ten years with major biopharmaceutical companies, Genedata Bioprocess has been adopted by multinational biopharmaceuticals as well as innovative biotech companies, especially in the RNA and cell & gene therapy space. The platform integrates all data generated along the biotherapeutics development and CMC process, including cell line development, upstream, downstream, and analytics functions. It enables fully automated processes, such as streamlining highly parallelized scale-down expression experiments with mini-bioreactors. In addition, by providing an integrated platform across research and development, it accelerates and improves the drug candidate transition from research to development. Built on a modular and scalable architecture, the system is suitable for installations ranging from single-site groups to global, multi-site biopharma development organizations.

“We are delighted to see Light Chain Bioscience expanding their usage of the Genedata Biopharma Platform to now integrate both their discovery and development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We have identified the R2D transition as one of the main bottlenecks in the biopharma industry. We are pleased to see that our integrated R&D workflow platform helps our customers to overcome this challenge by reducing process complexity, automating operations, streamlining data exchange with CDMOs, and ultimately, increasing efficiency.”

About Light Chain Bioscience

Light Chain Bioscience is a clinical-stage company focused on the discovery and development of therapies based on bispecific and multi-specific antibody formats. Its proprietary κλ body platform allows for the identification of bispecific antibodies that fully retain the native sequence and structure of human antibodies. This unique property is of interest for long term treatment of patients. In immuno-oncology, Light Chain Bioscience focuses on the selective targeting of the checkpoint CD47 as well as T cell and activation redirecting strategies.
www.lightchainbio.com